Why Gritstone Bio (GRTS) Stock Is Down 64% Today
Why Gritstone Bio (GRTS) Stock Is Down 64% Today
Gritstone bio Inc. (NASDAQ:GRTS) shares are trading lower by 64.2% to $0.07 during Thursday's session after the company announced it voluntarily filed for Chapter 11 restructuring.
Gritstone bio公司（納斯達克：GRTS）股價在週四交易日下跌64.2%，至0.07美元，因該公司宣佈自願申請進行第11章重組。
What Else: Gritstone Bio says the company plans to use the court-supervised restructuring to preserve value while exploring strategic alternatives. Gritstone is in talks with a potential bidder or plan sponsor and hopes to present a deal to the court soon.
此外：Gritstone Bio表示，公司計劃利用法院監督的重組來保留價值，同時探討戰略選擇。Gritstone正與潛在競標者或計劃發起者進行談判，希望儘快向法院提出交易方案。
The company also says it remains focused on developing next-generation vaccines and immunotherapies, including its promising GRANITE cancer treatment, while continuing normal operations during the bankruptcy process. Gritstone added that the company aims to minimize the impact on employees, vendors and stakeholders through "first day" motions.
公司還表示，公司仍專注於開發下一代疫苗和免疫療法，包括備受期待的GRANITE癌症治療，同時在破產過程中繼續正常運營。Gritstone補充說，公司旨在通過「首日」動議儘量減少對員工、供應商和利益相關者的影響。
Read Also: Delta's Turbulent Q3: Mixed Results And Tech Troubles Cloud Holiday Outlook
閱讀更多：達美航空動盪的第三季度：業績起伏和技術問題矇蔽假期前景
According to data from Benzinga Pro, GRTS has a 52-week high of $3.33 and a 52-week low of $0.07.
根據Benzinga Pro的數據，GRTS的52周最高價爲3.33美元，52周最低價爲0.07美元。
譯文內容由第三人軟體翻譯。
